MarketCap
Facebook
X
Telegram
Humanigen EBITDA | HGEN
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Humanigen
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -68.3 M | -233 M | -88.2 M | -8.94 M | -11.3 M | -19 M | -18.7 M | -34.2 M | -36.4 M | -9.63 M | -23.3 M | -1.78 M | -5.39 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.78 M | -233 M | -42.9 M |
Quarterly EBITDA Humanigen
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.24 M | - | -22.7 M | -29.4 M | -20.5 M | - | -66 M | -70.1 M | -64.4 M | - | -30.7 M | -23.1 M | -2.06 M | - | -2.03 M | -2.96 M | -2.23 M | - | -2.32 M | -2.59 M | -4.64 M | - | -5.76 M | -5.37 M | -5.1 M | - | -4.11 M | -6.81 M | -2.88 M | - | -6.06 M | -5.54 M | -9.29 M | -9.32 M | -7.46 M | -9.3 M | -10.1 M | -9.93 M | -10.9 M | -11.5 M | -8.28 M | -11.9 M | -8.14 M | -2.01 M | -1.09 M | - | -550 K | -859 K | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -550 K | -70.1 M | -12.9 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
-75.9 M | $ 5.32 | 0.09 % | $ 652 M |  USA |
 |
ADC Therapeutics SA
ADCT
|
-121 M | $ 1.05 | 0.46 % | $ 133 M |  Schweiz |
 |
Agenus
AGEN
|
-10.2 M | $ 7.21 | 0.7 % | $ 214 M | USA |
 |
Фармсинтез
LIFE
|
-22.6 M | - | - | - |  Russia |
 |
Akebia Therapeutics
AKBA
|
24.8 M | $ 0.92 | 1.64 % | $ 237 M | USA |
 |
Alector
ALEC
|
-150 M | $ 1.93 | 0.81 % | $ 199 M | USA |
 |
Amryt Pharma plc
AMYT
|
-38.6 M | - | - | $ 621 M |  Britain |
 |
Aligos Therapeutics
ALGS
|
-87.1 M | $ 5.05 | 1.2 % | $ 49.9 M | USA |
 |
Alkermes plc
ALKS
|
281 M | $ 46.07 | 0.09 % | $ 7.59 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
-197 M | $ 1.69 | 0.58 % | $ 373 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
557 M | $ 239.36 | 0.46 % | $ 31.4 B | USA |
 |
Altimmune
ALT
|
-94.4 M | $ 3.24 | 0.31 % | $ 285 M | USA |
 |
ALX Oncology Holdings
ALXO
|
-103 M | $ 1.76 | 0.53 % | $ 94.4 M | USA |
 |
Evelo Biosciences
EVLO
|
-106 M | - | -14.46 % | $ 27.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
172 M | $ 23.95 | 1.31 % | $ 1.12 B | USA |
 |
AnaptysBio
ANAB
|
48.5 M | $ 54.31 | 0.15 % | $ 1.56 B | USA |
 |
Anika Therapeutics
ANIK
|
-5.68 M | $ 20.84 | 0.24 % | $ 299 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
203 M | $ 73.59 | 2.05 % | $ 1.48 B | USA |
 |
Aptevo Therapeutics
APVO
|
-26.1 M | $ 1.72 | 0.58 % | $ 543 K | USA |
 |
Allakos
ALLK
|
-115 M | - | - | $ 28.6 M | USA |
 |
Aquestive Therapeutics
AQST
|
-70.5 M | $ 4.82 | 0.21 % | $ 515 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-73.2 M | $ 15.6 | 0.25 % | $ 427 M |  Israel |
 |
Armata Pharmaceuticals
ARMP
|
-35.1 M | $ 4.07 | 2.21 % | $ 147 M | USA |
 |
Assembly Biosciences
ASMB
|
-12 M | $ 25.48 | 0.54 % | $ 286 M | USA |
 |
Actinium Pharmaceuticals
ATNM
|
-36.1 M | $ 1.24 | 0.79 % | $ 38.7 M | USA |
 |
AbbVie
ABBV
|
15.8 B | $ 262.51 | 0.01 % | $ 464 B | USA |
 |
Atara Biotherapeutics
ATRA
|
38 M | $ 10.11 | 7.1 % | $ 127 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
52.7 M | $ 16.96 | 5.15 % | $ 2.28 B |  Canada |
 |
Autolus Therapeutics plc
AUTL
|
-262 M | $ 1.87 | 0.53 % | $ 498 M | Britain |
 |
Atea Pharmaceuticals
AVIR
|
-180 M | $ 5.15 | 1.24 % | $ 420 M | USA |
 |
Axon Enterprise
AXON
|
21.1 M | $ 468.42 | 5.96 % | $ 36.6 B | USA |
 |
Axsome Therapeutics
AXSM
|
-166 M | $ 211.97 | 3.87 % | $ 10.5 B | USA |
 |
Aytu BioScience
AYTU
|
-2.45 M | $ 1.97 | 0.5 % | $ 12.4 M | USA |
 |
BridgeBio Pharma
BBIO
|
-518 M | $ 68.3 | 0.1 % | $ 13.1 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
-241 M | $ 3.64 | 0.68 % | $ 252 M | Britain |
 |
Black Diamond Therapeutics
BDTX
|
12.8 M | $ 1.94 | 1.02 % | $ 110 M | USA |
 |
Beam Therapeutics
BEAM
|
-361 M | $ 23.1 | 0.15 % | $ 2.28 B | USA |
 |
Biogen
BIIB
|
780 M | $ 216.01 | 0.42 % | $ 31.6 B | USA |
 |
BioLineRx Ltd.
BLRX
|
-10.3 M | $ 2.48 | 0.79 % | $ 6.11 B | Israel |
 |
AbCellera Biologics
ABCL
|
-199 M | $ 11.67 | 2.28 % | $ 3.49 B | Canada |
 |
Benitec Biopharma
BNTC
|
-51.1 M | $ 11.04 | 0.9 % | $ 514 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.4 M | - | - | $ 231 M | USA |
 |
Burford Capital Limited
BUR
|
232 M | $ 3.87 | 0.8 % | $ 848 M | Britain |
 |
Clovis Oncology
CLVS
|
-44.2 M | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
-96.5 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-76 M | - | - | $ 401 M | USA |
 |
Cabaletta Bio
CABA
|
-171 M | $ 2.49 | 0.39 % | $ 250 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.93 M | $ 2.24 | 0.89 % | $ 3.69 M | Israel |
 |
Catalyst Biosciences
CBIO
|
14 M | $ 17.18 | 1.7 % | $ 1.53 B | USA |
 |
C4 Therapeutics
CCCC
|
-113 M | $ 3.45 | 0.58 % | $ 286 M | USA |